Bufexamac
General information:
| Withdrawn ID: | w207 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | M01AB17 |
| M02AA09 | |
| Molecular Formula: | C12H17NO3 |
| Molweight: | 223.271 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First approved: | 1991 |
| First withdrawn: | 2010 |
| Last withdrawn: | 2010 |
| Reference: | https://www.ncbi.nlm.nih.gov/pubmed/23476663 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Bufexamac as primary suspect: | 2 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 2 |
|---|---|
| Life-Threatening condition: | 2 |
Reported side-effects:
| Side-effect | Case number |
|---|---|
| GASTROINTESTINAL INJURY | 2 |
| TOXIC EPIDERMAL NECROLYSIS | 2 |
| SKIN BACTERIAL INFECTION | 2 |
| PSEUDOMONAS INFECTION | 2 |
| LIP HAEMORRHAGE | 2 |
| LARYNGEAL OEDEMA | 2 |
| KLEBSIELLA INFECTION | 2 |
| HYPERTENSIVE CRISIS | 2 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2 |
| ACINETOBACTER INFECTION | 2 |
| FUNGAL SKIN INFECTION | 2 |
| FEEDING DISORDER | 2 |
| ENTEROCOCCAL INFECTION | 2 |
| DIARRHOEA | 2 |
| CHOLESTASIS | 2 |
| Hepatocellular injury | 1 |
| CYTOLYTIC HEPATITIS | 1 |
| CANDIDIASIS | 1 |
| Candida infection | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| Q16637 | 1412.5 | Survival motor neuron protein | SMN_HUMAN |
| Q16665 | 7943.3 | Hypoxia-inducible factor 1-alpha | HIF1A_HUMAN |
Toxicity information:
| Toxicity class: | 5 |
|---|---|
| Toxicity type: | multiple |
| LD50: | 2900 mg/kg |
External links:
| ChEBML: | CHEMBL94394 |
|---|---|
| DrugBank: |